Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck’s CV Pipeline: A Shrinking But Strident Commitment

Executive Summary

Merck insists it is committed to its cardiovascular franchise, but the company has had to halt the development of several CV assets and has been plagued by poor trial results for others.

You may also be interested in...

Cardio And Metabolic Deals, Launches Falter – Will Innovation Help?

Despite the high unmet medical need in the cardiovascular and metabolic indications, companies are increasingly reluctant to make deals in the sector. But unique therapeutic approaches to diseases could bring new life.

Is Rapid Cost-cutting The Answer To Merck’s R&D Woes?

The Big Pharma has had plenty of problems with its pipeline in recent years but has taken steps to move the needle back in the right direction. For some analysts and investors that progress is not coming rapidly enough.

IMPROVE-IT Go-Ahead Gives Merck Temporary Reprieve On Vytorin

Large outcomes study of Vytorin (ezetimibe/simvastatin) is allowed to carry on, reassuring investors that significant safety problems are unlikely to emerge. The development coincides with release of full results from the outcomes trial HPS2-THRIVE, in which Merck’s niacin-containing Tredaptive proved unsafe as well as ineffective.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts